UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The ...
Astrazeneca (AZN) closed the latest trading day at $70.25, indicating a +0.95% change from the previous session's end. This move outpaced the S&P 500's daily loss of 0.47%. Meanwhile, the Dow ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.
In the latest trading session, Astrazeneca (AZN) closed at $66.58, marking a -0.09% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. Elsewhere ...
For this reason, we prefer to remain neutral. Since our last update, when we downgraded AstraZeneca's (NASDAQ:AZN) rating to Neutral, the company's stock price has declined (Fig 1). Over the ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.